The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers uncovered clues explaining risks of heart disease, lung disease, Covid-19 and… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, results showed the new Wegovy pill could help patients lose 17% of… Read More
News round-up for 15 June – 19 June by Bruno Quinney, Content Team at DDW. This week, results show the new Wegovy pill could help patients lose 17% of their body weight. Elsewhere, advances have been made in both cancer treatment and cancer research. The top stories: … Read More
Results presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from the Phase III FIGHT-302 trial showed that Incyte’s pemigatinib (Pemazyre), significantly improved progression-free survival in the first-line setting in cholangiocarcinoma (bile duct cancer). The drug was compared with gemcitabine and cisplatin, a long-standing… Read More
The European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Rretifanlimab is the first systemic treatment for adult patients with advanced… Read More
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy). If it is approved by the European Commission it will be the first… Read More
The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD). It is approved for use after the failure of at least two prior lines of systemic therapy in adult and paediatric… Read More
